Drug intelligence / Profile preview

bifidobacterium animalis subsp. lactis BLa80

Development stage: Preclinical
Lead developer: Wecare Probiotics
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium animalis subsp. lactis BLa80 is a commercial probiotic strain being investigated for its therapeutic effects. A preclinical study in a mouse model of ulcerative colitis (UC) demonstrated that BLa80 could alleviate symptoms, reduce intestinal inflammation, and decrease serum levels of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-17. The mechanism involves modulating the gut microbiota by increasing its diversity and selectively promoting the growth of beneficial bacteria, including Romboutsia and Adlercreutzia. BLa80 is produced by Wecare-bio Probiotics (Suzhou) Co., Ltd. Additionally, it is being evaluated in a clinical trial as an adjuvant treatment for children with acute watery diarrhea.

Other names: 动物双歧杆菌乳亚种BLa80

Beyond the preview

Go deeper on bifidobacterium animalis subsp. lactis BLa80.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium animalis subsp. lactis BLa80.

Explore the full profile